EU regulator backs revoking Amgen's right to sell rare-disease drug - Reuters
EU regulator backs revoking Amgen's right to sell rare-disease drug Reuters
Amgen Company News
EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks - MedCity News
EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks MedCity News
Europe's CHMP reverses endorsement of Tavneos as Amgen FDA hearing looms - Fierce Pharma
Europe's CHMP reverses endorsement of Tavneos as Amgen FDA hearing looms Fierce Pharma
900,000 Bottles of Heart and Kidney Medications Recalled For 'Unexpected Foreign Matter' in Bottles - People.com
900,000 Bottles of Heart and Kidney Medications Recalled For 'Unexpected Foreign Matter' in Bottles People.com
Amgen Named Among World’s Most Impactful Companies 2026 by TIME - Amgen
Amgen Named Among World’s Most Impactful Companies 2026 by TIME Amgen
Amgen Inc. (AMGN) Price Target Raised to $303 After Q1 Model Update - Yahoo Finance
Amgen Inc. (AMGN) Price Target Raised to $303 After Q1 Model Update Yahoo Finance
Inside FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
Inside FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation Bloomberg.com
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked - WSJ
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked WSJ
What Does Rep. Salazar's Amgen Purchase Signify for Biotech Investors - Kavout | AI
What Does Rep. Salazar's Amgen Purchase Signify for Biotech Investors Kavout | AI
FDA approves Viridian eye drug, stoking competition with Amgen’s Tepezza - Endpoints News
FDA approves Viridian eye drug, stoking competition with Amgen’s Tepezza Endpoints News
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains MarketWatch
Amgen Continues To Perform (NASDAQ:AMGN) - Seeking Alpha
Amgen Continues To Perform (NASDAQ:AMGN) Seeking Alpha
Amgen Inc. Stock 12‑Month Price Target Cut to $350.22 - TradingView
Amgen Inc. Stock 12‑Month Price Target Cut to $350.22 TradingView
A pharmaceutical company is trying to block Colorado’s first-in-the-nation drug price cap in court - The Colorado Sun
A pharmaceutical company is trying to block Colorado’s first-in-the-nation drug price cap in court The Colorado Sun
How Should Investors Weigh the Trade-Off Between Amgen and Iovance? - NAI500
How Should Investors Weigh the Trade-Off Between Amgen and Iovance? NAI500
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - Amgen
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Inc. stock outperforms competitors on strong trading day MarketWatch
Amgen faces EU withdrawal of rare-disorder therapy Tavneos - Seeking Alpha
Amgen faces EU withdrawal of rare-disorder therapy Tavneos Seeking Alpha
Amgen CEO Bob Bradway's 2025 Letter to Shareholders - Amgen
Amgen CEO Bob Bradway's 2025 Letter to Shareholders Amgen
Is Amgen Inc. (AMGN) A Good Stock To Buy Now? - Yahoo Finance
Is Amgen Inc. (AMGN) A Good Stock To Buy Now? Yahoo Finance
FDA declines to approve Sobi's gout therapy on concerns over manufacturing - Reuters
FDA declines to approve Sobi's gout therapy on concerns over manufacturing Reuters
Amgen Named One of the 2026 World’s Most Ethical Companies® by Ethisphere - Amgen
Amgen Named One of the 2026 World’s Most Ethical Companies® by Ethisphere Amgen
An Important Update Regarding TAVNEOS® (avacopan) - Amgen
An Important Update Regarding TAVNEOS® (avacopan) Amgen
Amgen’s Stock Is Down 10% From Its Highs: The $10 Billion Obesity Drug Bet That Could Define the Next Decade - TIKR.com
Amgen’s Stock Is Down 10% From Its Highs: The $10 Billion Obesity Drug Bet That Could Define the Next Decade TIKR.com
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PR Newswire
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape PR Newswire
Amgen owes $20.2 million in antibody patent lawsuit, US jury says - Reuters
Amgen owes $20.2 million in antibody patent lawsuit, US jury says Reuters
Amgen Named One of Newsweek’s Most Trustworthy Companies in America 2026 - Amgen
Amgen Named One of Newsweek’s Most Trustworthy Companies in America 2026 Amgen
Amgen (AMGN) Stock Could Be 2.1% Undervalued After Patent Verdict - simplywall.st
Amgen (AMGN) Stock Could Be 2.1% Undervalued After Patent Verdict simplywall.st
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE - Amgen
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE Amgen
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance
Highlights from Amgen's 2025 Fourth Quarter and Full Year Earnings Report - Amgen
Highlights from Amgen's 2025 Fourth Quarter and Full Year Earnings Report Amgen
Amgen (AMGN) Faces EU Withdrawal Risk for Tavneos Due to Data In - GuruFocus
Amgen (AMGN) Faces EU Withdrawal Risk for Tavneos Due to Data In GuruFocus
Enterprise value to EBIT forward of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGDB - TradingView
Enterprise value to EBIT forward of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGDB TradingView
Amgen loses in Harbour antibody patent case, ordered to pay $20M+ - Fierce Biotech
Amgen loses in Harbour antibody patent case, ordered to pay $20M+ Fierce Biotech
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance
2025 at Amgen: Investing, Expanding, and Serving More Patients - Amgen
2025 at Amgen: Investing, Expanding, and Serving More Patients Amgen
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS - PR Newswire
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS PR Newswire
Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential - Insider Monkey
Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential Insider Monkey
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE - Amgen
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE Amgen